Viewing nowDanubia Tablet 50 mg (Sitagliptin Hydrochloride Monohydrate)
Sitagliptin Hydrochloride Hydrate 56.69mg
Tablet · Prescription medication
KS Pharm Co., Ltd.

MFDS item code 202102660 · Approved 2021.03.26 · Insurance code 059001080
Improvement of glycemic control in patients with type 2 diabetes
This drug is used to improve blood sugar control in patients with type 2 diabetes. Initially, it may be administered as monotherapy, and if blood sugar control is insufficient, it is used in combination with other antidiabetic agents including metformin. If blood sugar control remains difficult with monotherapy or combination therapy with sulfonylureas, metformin, thiazolidinediones, or insulin, this drug can be added for more effective blood sugar management. Thus, it is used beneficially in the treatment of type 2 diabetes in combination with various therapies.
This medicine is administered at 100 mg once daily, either as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, section 5. General Precautions). Patients with renal impairment Because dosage adjustment according to renal function is necessary, assessment of renal function before and periodically after starting this medicine is recommended. 1. No dosage adjustment is necessary in patients with mild renal impairment (eGFR ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (eGFR ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (eGFR ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.
This drug may cause severe allergic reactions, so if symptoms such as skin rash or difficulty in breathing occur, use should be stopped immediately, and a doctor should be consulted. Severe inflammation of the pancreas, known as acute pancreatitis, may occur, so if symptoms such as abdominal pain or vomiting arise, this drug should be discontinued immediately, and medical personnel should be informed. It should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and it should not be administered if there is an allergy to this drug or its components. Patients with impaired kidney function may experience delayed excretion of this drug, requiring dosage adjustment, and regular kidney function tests are important. The risk of hypoglycemia may increase when this drug is used in conjunction with other hypoglycemic agents; thus, caution should be exercised for hypoglycemic symptoms when used with insulin or sulfonylureas. Serious side effects such as arthralgia or vesicular skin rash may occur during treatment, and if such symptoms occur, a doctor should be notified immediately. Use in pregnant or breastfeeding women is not recommended, and the safety and efficacy in children under 18 years of age have not been established. In case of overdose, immediate medical attention should be sought for appropriate treatment, and this drug can be partially removed by hemodialysis. This drug has a low potential for interactions with other medications, but it is advisable to consult with healthcare personnel when taking specific medications. Elderly patients may have reduced kidney function and require dosage adjustments and monitoring of kidney function.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a sealed container to prevent air ingress and should be kept at room temperature between 1 to 30 degrees Celsius. This helps maintain the drug's effectiveness and prevents deterioration.
Bright yellow-orange round film-coated tablet
100 tablets/bottle, 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Hydrochloride Hydrate 56.69mg
Tablet · Prescription medication
KS Pharm Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.